Prosecution Insights
Last updated: October 02, 2026
Application No. 18/696,415

PERSONAL CARE COMPOSITION AND PERSONAL CARE PRODUCT

Non-Final OA §103§112
Filed
Mar 28, 2024
Priority
Oct 04, 2021 — provisional 63/251,875 +2 more
Examiner
MAEWALL, SNIGDHA
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Edgewell Personal Care Brands LLC
OA Round
1 (Non-Final)
59%
Grant Probability
Moderate
1-2
OA Rounds
10m
Est. Remaining
69%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
630 granted / 1072 resolved
-1.2% vs TC avg
Moderate +10% lift
Without
With
+10.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
48 currently pending
Career history
1124
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
52.2%
+12.2% vs TC avg
§102
8.5%
-31.5% vs TC avg
§112
18.6%
-21.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1072 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detailed Action Restriction/Election Applicant’s election without traverse of Species 1: glycerin as in claims 1-15 and 18-20; 2. Species 2: avobenzone as in claims 1-6, 8-15, and 18-20; 3. Species 3: propylene glycol as in claims 1-12 and 18-20; and 4. Species 5: sodium polyacrylate as in claims 1-15 and 18-20, in the reply filed on 08/05/26 is acknowledged. Claims 7 and13-14 withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 08/05/26. Claim Rejections - 35 USC § 112, indefiniteness The following is a quotation of 35 U.S.C. 112(b): The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-6, 8-12, 15 and 18-20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 1 recites a limitation “primary emulsifier” which is a relative term and makes the claim indefinite. The term “primary” in claim 1 is a relative term which renders the claim indefinite. The term “primary” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Applicant suggests reciting claim 4 in a Markush format as “selected from the group consisting of”. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-6, 8-12 and 15 are rejected under 35 U.S.C. 103 as being unpatentable over (Mintel GNPD Record ID 9025652 "Anti Stains Caring Roll-On SPF 50+", Sep 2021, XP93008357, presented in IDS). Mintel shows a composition comprising a sunscreen filter (homosalate, butyl methoxydibenzoylmethane, ethylhexylsalicylate, bis-ethylhexyloxyphenol methoxyphenyl triazine, ethylhexyl triazone), water as major component, and glycerin as the component present in the third highest amount, in a roll-on applicator. Mintel teaches propylene glycol in ingredients. Thus, the art teaches use of a sunscreen composition/formulations comprising a sunscreen filter, water, glycerin. This combination is not in a single embodiment. However, all the claimed elements were known in the prior art and one skilled in the art could have combined the elements as claimed by known methods with no change in their respective functions, and the combination yielded nothing more than predictable results of making a sunscreen composition in a personal care product, see MPEP 2143 part (I)(A). Amount of the component is a result effective variable and one of ordinary skill would have manipulated the amounts in order to obtain optimum sunscreen filter composition. Claims 1-6, 8-12, 15 and 18-20 are rejected under 35 U.S.C. 103 as being unpatentable over Delaune et al. (WO 2019/121442A1, presented in IDS) Delaune et al. discloses in Table 1 an O/W emulsion comprising sunscreen filter (octocrylene, BMDM, ethylhexyl salicylate, MBBT), 40-90% water (ca.59%), a dispensing agent including a polyol (glycerin), and a co- emulsifier (cetyl alcohol). No primary emulsifier is used. Propylene glycol is taught on pages 10 and 13. Thus, the art teaches use of a sunscreen composition/formulations comprising a sunscreen filter, water, glycerin. This combination is not in a single embodiment. However, all the claimed elements were known in the prior art and one skilled in the art could have combined the elements as claimed by known methods with no change in their respective functions, and the combination yielded nothing more than predictable results of making a sunscreen composition in a personal care product, see MPEP 2143 part (I)(A). Amount of the component is a result effective variable and one of ordinary skill would have manipulated the amounts in order to obtain optimum sunscreen filter composition. Claims 1-6, 8-12, 15 and 18-20 are rejected under 35 U.S.C. 103 as being unpatentable over Siefken et al. (US PG 2021/145722 A1). Siefken et al. discloses in formulations 5 to 7 sunscreen compositions which do not comprise the "primary emulsifiers", which comprise "co-emulsifiers", as well as polyol. For example, formulation 6 comprises sunscreen filter (octocrylene, titanium dioxide), 40-90% water (ca.69%), a dispensing agent including a polyol (glycerin), and a co-emulsifier (2.0% cetyl alcohol, 0.4% sodium polyacrylate). No primary emulsifier is used. Propylene glycol is listed in Table 17. Thus, the art teaches use of a sunscreen composition/formulations comprising a sunscreen filter, water, glycerin. This combination is not in a single embodiment. However, all the claimed elements were known in the prior art and one skilled in the art could have combined the elements as claimed by known methods with no change in their respective functions, and the combination yielded nothing more than predictable results of making a sunscreen composition in a personal care product, see MPEP 2143 part (I)(A). Amount of the component is a result effective variable and one of ordinary skill would have manipulated the amounts in order to obtain optimum sunscreen filter composition. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to SNIGDHA MAEWALL whose telephone number is (571)272-6197. The examiner can normally be reached Monday thru Friday; 8:30 AM to 5PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana S. Kaup can be reached on 571-272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SNIGDHA MAEWALL/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Mar 28, 2024
Application Filed
Sep 09, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746304
NANOCOMPOSITE FIBERS WITH A DRAMATIC REDUCTION IN HUMAN PLASMA COAGULATION TIME
5y 2m to grant Granted Sep 29, 2026
Patent 12734497
HIGH AMYLOSE STARCH BASED CAPSULES AND METHOD OF MAKING SAME
5y 4m to grant Granted Sep 15, 2026
Patent 12733639
HESPERALOE EXTRACT FOR FOLIAR USE
2y 9m to grant Granted Sep 15, 2026
Patent 12728077
TOOTH MINERALIZATION SOLUTION AND MINERALIZATION METHOD THEREOF
4y 10m to grant Granted Sep 08, 2026
Patent 12721926
MEDICAL ARTICLE WITH BACKING
5y 3m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
59%
Grant Probability
69%
With Interview (+10.5%)
3y 4m (~10m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1072 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month